Erlotinib - Astellas Pharma/Roche

Drug Profile

Erlotinib - Astellas Pharma/Roche

Alternative Names: CP-358774; CP-358774-01; Erlotinib hydrochloride; NSC-718781; OSI-774; R-1415; RG-1415; RO-508231; Ro50-8231; Tarceva

Latest Information Update: 17 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OSI Pharmaceuticals
  • Developer Alliance for Clinical Trials in Oncology; Astellas Pharma; Chugai Pharmaceutical; Finnish Lung Cancer Group; Genentech; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Novartis; OSI Pharmaceuticals; Polyphenon Pharma; Roche; SCRI Development Innovations; Takeda Oncology; University of Texas M. D. Anderson Cancer Center; Wake Forest University School of Medicine
  • Class Alkynes; Antineoplastics; Quinazolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer; Pancreatic cancer
  • Phase III Ependymoma; Head and neck cancer
  • Phase II Bladder cancer; Brain metastases; Glioblastoma; Gynaecological cancer; Neuroendocrine tumours; Squamous cell cancer
  • Phase I/II Colorectal cancer; Myelodysplastic syndromes
  • Phase I Solid tumours
  • No development reported Anaplastic astrocytoma; Breast cancer; Bronchiolo-alveolar adenocarcinoma; Cancer metastases
  • Discontinued Liver cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 05 Jun 2018 Astellas Pharma terminates a phase II trial due to slow accrual in Pancreatic cancer (Combination therapy, Adjuvant therapy, Neoadjuvant therapy, Late-stage disease) in Canada, USA (PO)
  • 04 Jun 2018 The National Cancer Institute terminates a phase II trial for Non-small cell lung cancer (combination therapy, newly diagnosed, late stage disease, Inoperable/unresectable) in the USA (NCT01822496)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top